Alexander Schuth Sells 2,768 Shares of Denali Therapeutics (NASDAQ:DNLI) Stock

Posted by Francis Steltz on Sep 5th, 2026

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) insider Alexander Schuth sold 2,768 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $23.44, for a total transaction of $64,881.92. Following the transaction, the insider owned 278,995 shares of the company’s stock, valued at approximately $6,539,642.80. The trade was a 0.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Denali Therapeutics Trading Down 2.3%

NASDAQ:DNLI opened at $22.28 on Friday. Denali Therapeutics Inc. has a 52 week low of $12.58 and a 52 week high of $27.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. The firm’s fifty day moving average is $24.44 and its 200-day moving average is $21.83. The firm has a market cap of $3.56 billion, a P/E ratio of -7.85 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $2.15 million. During the same period in the previous year, the company earned ($0.72) earnings per share. Equities analysts expect that Denali Therapeutics Inc. will post -2.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

DNLI has been the topic of a number of recent analyst reports. B. Riley Financial boosted their price objective on Denali Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Friday, July 17th. Deutsche Bank Aktiengesellschaft increased their price target on Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Stifel Nicolaus set a $41.00 price objective on shares of Denali Therapeutics in a research report on Monday, June 22nd. Finally, Wedbush reiterated an “outperform” rating and issued a $26.00 price objective on shares of Denali Therapeutics in a research note on Monday, July 13th. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $35.85.

View Our Latest Research Report on DNLI

Hedge Funds Weigh In On Denali Therapeutics

A number of large investors have recently modified their holdings of DNLI. Bank of America Corp DE lifted its stake in shares of Denali Therapeutics by 21.7% in the first quarter. Bank of America Corp DE now owns 1,134,183 shares of the company’s stock valued at $21,776,000 after buying an additional 202,039 shares in the last quarter. Great Lakes Advisors LLC acquired a new stake in shares of Denali Therapeutics in the 2nd quarter worth about $3,731,000. E. Ohman J or Asset Management AB bought a new position in Denali Therapeutics in the 2nd quarter valued at about $4,115,000. Sei Investments Co. bought a new position in Denali Therapeutics in the 1st quarter valued at about $1,003,000. Finally, UBS Group AG boosted its stake in Denali Therapeutics by 19.5% during the 4th quarter. UBS Group AG now owns 2,404,704 shares of the company’s stock valued at $39,702,000 after purchasing an additional 392,351 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Company Profile

(Get Free Report)

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.